AGLE - Aeglea BioTherapeutics, Inc.
9.57 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 10.02 |
| Open | 9.75 |
| Bid | 7.00 x 800 |
| Ask | 11.25 x 800 |
| Day's Range | 9.08 - 10.10 |
| 52 Week Range | 3.75 - 12.00 |
| Volume | 274,825 |
| Avg. Volume | 221,501 |
| Market Cap | 211.321M |
| Beta (3Y Monthly) | 0.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.81 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
- GlobeNewswire•16 hours ago
Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced new positive interim clinical data at the 2018 American Society of Human Genetics (ASHG) Conference from its ongoing Phase 1/2 trial of pegzilarginase, its lead investigational therapy, in patients with the rare genetic disease Arginase 1 Deficiency (ARG1-D). “Our clinical experience with ARG1-D and pegzilarginase has advanced rapidly given the accelerated enrollment over the last few months.
- GlobeNewswire•8 days ago
Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting
Company to Host Clinical Update Conference Call on October 17 at 8:30 a.m. ET Aeglea to Present Literature Review on Arginase 1 Deficiency Positive Preclinical Efficacy.
- GlobeNewswire•17 days ago
FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to the Company’s lead product candidate, pegzilarginase, for the treatment of Arginase 1 Deficiency. This designation by the FDA confirms Aeglea’s eligibility to receive a rare pediatric disease priority review voucher (PRV) upon approval of a biologics license application (BLA) for pegzilarginase.
- Simply Wall St.•19 days ago
Is Now The Right Time To Invest In Healthcare And Aeglea BioTherapeutics Inc (NASDAQ:AGLE)?
Aeglea BioTherapeutics Inc (NASDAQ:AGLE), a US$204.7m small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of Read More...
- GlobeNewswire•last month
Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
AUSTIN, Texas, Sept. 17, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- Benzinga•last month
Aeglea Plunges On Updated Data For Arginase 1 Deficiency Candidate, Wells Fargo Downgrade
Shares of Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) were slumping Tuesday following the release of data from an early-to-mid- stage trial of its lead product candidate pegzilarginase for treating Arginase 1 deficiency, or ARG1-D. ARG1-D is a debilitating urea cycle disorder caused by deficiency of a key arginine metabolizing enzyme, leading to neurological abnormalities, hyperammonemia and early mortality. Wells Fargo Securities downgraded shares of Aeglea from Outperform to Market Perform following the data release.
- GlobeNewswire•2 months ago
Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference
AUSTIN, Texas, Aug. 28, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- GlobeNewswire•2 months ago
Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 SSIEM Annual Symposium
AUSTIN, Texas, Aug. 27, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- Motley Fool•2 months ago
George Soros Bought This Under-the-Radar Biotech Stock: Should You?
Soros Fund Management picked up a healthy stake in rare-disease and cancer drugmaker Aeglea BioTherapeutics in the second quarter.
- Associated Press•2 months ago
Aeglea: 2Q Earnings Snapshot
On a per-share basis, the Austin, Texas-based company said it had a loss of 46 cents. The biopharmaceutical company posted revenue of $2.4 million in the period. Aeglea shares have climbed 67 percent since ...
- GlobeNewswire•2 months ago
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
AUSTIN, Texas, Aug. 09, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- GlobeNewswire•3 months ago
Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule
Company Will Provide New Interim Data for Pegzilarginase in Patients with Arginase 1 Deficiency. Preclinical Efficacy Data of AEB4104- a New Enzyme Approach- for the treatment of Homocystinuria. Three-Conference ...
- Zacks•3 months ago
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
- Zacks•4 months ago
Novo Nordisk (NVO) Announces Results in Diabetes Studies
Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.
- Zacks•4 months ago
Anika Reports Top Line Data from CINGAL Study, Shares Slump
Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.
- Zacks•4 months ago
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
- Zacks•4 months ago
Alexion (ALXN) Submits Application for ALXN1210 with FDA
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
- Zacks•4 months ago
Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug
Agios Pharmaceuticals, Inc. (AGIO), initiates a phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with PK deficiency who do not receive regular blood transfusions.
- Zacks•4 months ago
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
- Zacks•4 months ago
Flex Pharma Down on Workforce Reduction, Ends Phase II Study
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.
- Zacks•4 months ago
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA
Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.
- Benzinga•4 months ago
BMO: Aeglea Has A Potentially Market-Conquering Arginase Deficiency Candidate, Oncology Opportunity
Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) hasn’t received much attention in its two years on the market, but on Thursday it caught the eye of its fourth analyst and fourth bull. The Rating BMO Capital ...
